Bob Clay joins Kinapse in our newly created Chief Regulatory Officer role

Posted by Kinapse on 03 March 2014

Bob Clay joins Kinapse in our newly created Chief Regulatory Officer role and chair of our Regulatory Strategy Board. Bob brings to Kinapse an extensive track record in drug development and has held senior leadership positions in regulatory affairs at several companies including AstraZeneca and Pfizer. He has led projects in a wide range of therapeutic areas on a global basis and an interest in the impact of regulation on the development of innovative medicines and healthcare policy matters.

Bob is a pharmacist, registered in the UK, and began his career in industry as a formulation scientist before joining the UK licensing authority as a pharmaceutical reviewer. He is a member of the Expert Scientific Advisory Committee for Medicines for Malaria Venture and was recently elected to the board of TOPRA.

Advise · Build · Operate